Support

Licensing Opportunities

The La Jolla Institute for Immunology is a world-renowned research organization specializing in human immunology and its role in human disease. Our 20+ principal investigators have pioneered innovations in oncology, cardiovascular disease, autoimmunity and infectious diseases a number of which are in clinical development. One such technology, an anti-Ox40 antibody co-developed by LJI Principal Investigator Dr. Michael Croft, is a first-in-class drug for the treatment of atopic dermatitis. LJI is also pioneering novel vaccines and treatments for SARS-CoV-2, dengue, CMV and other viruses. In addition, LJI is a leader in the worldwide effort for identification and bioinformatic characterization of antigens, including management of the Immune Epitope Database (www.iedb.org) and the development of peptide pools used to diagnose viral infections, viral subtypes, and characterize immune response.

LJI and its researchers partner with companies in a variety of capacities, including, as scientific advisors, through sponsored research collaborations and by licensing technologies, including therapeutic and diagnostic assets. There are many LJI technologies available for licensing, some of which are listed below. LJI welcomes inquiries regarding licensing and other collaborative opportunities. Please contact us at techtransfer@lji.org and our business development group looks forward to making introductions to investigators and exploring how we can work together.